Vol 54, No 5 (2020)
Letter to the Editors
Published online: 2020-10-02
Immunocompromised myasthenia gravis patient not infected with SARS-CoV-2 after close exposure — what is the risk of COVID-19?
Abstract
Not available
Keywords: myasthenia gravisimmunosuppressionCOVID-19
References
- Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020; 410: 116648.
- Jacob S, Muppidi S, Guidon A, et al. International MG/COVID-19 Working Group. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020; 412: 116803.
- Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) 16-24 February 2020. Geneva: World Health Organization, 2020. www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.
- Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000; 55(1): 16–23.
- Anand P, Slama MCC, Kaku M, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020; 62(2): 254–258.
- Thng ZX, De Smet MD, Lee CS, et al. COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. Br J Ophthalmol. 2020 [Epub ahead of print].
